43rd week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110262354 | CYANINE-CONTAINING COMPOUNDS FOR CANCER IMAGING AND TREATMENT - This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields. | 2011-10-27 |
20110262356 | Active Particles for Bio-Analytical Applications and Methods for Preparation Thereof - Luminescent and/or electroactive nanoparticles suitable for MRI (Magnetic Resonance Imaging) and/or PET (Positron Emission Tomography) are prepared by mixing luminescent or electroactive compounds and ethyl oxide/propyl oxide block-copolymers in an organic solvent, which is thereafter evaporated in order to obtain a residue; and by hydrolyzing-condensating tetraalkoxysilanes in an aqueous solution in the presence of the residue; the obtained nanoparticles show no or a negligible release of the luminescent or electroactive compounds and are useful for bio-analytic and bio-medic applications. | 2011-10-27 |
20110262357 | Metalloporphyrin Derivatives, Nanoparticles Comprising the Same, and Use Thereof for Photodynamic Therapy - Nanovectors are disclosed that make it possible to simultaneously target, image, and treat cancerous cells using photodynamic therapy. Also disclosed are novel molecules (I) derived from porphyrins, silica-based nanoparticles comprising the same, and their use in photodynamic therapy. | 2011-10-27 |
20110262358 | MOLECULAR MARKER FOR CANCER STEM CELL - A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker. | 2011-10-27 |
20110262359 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF - The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug. | 2011-10-27 |
20110262361 | EFFECTIVE NEW DRUG TARGET FOR THE TREATMENT OF TUBERCULOSIS - The present invention allows a screening method for identifying novel drugs for the treatment of tuberculosis as well as a diagnostic method for identifying clinical strains that are resistant to these novel drugs. In particular, the present invention relates to a method for screening in vitro drug candidates for the treatment of tuberculosis by interfering with the arabinogalactan biosynthesis, the said method comprising a step of putting into contact a | 2011-10-27 |
20110262362 | METHODS FOR TREATING OBESITY - The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed. | 2011-10-27 |
20110262363 | GLUCOSE BIOSENSOR SYSTEM COUPLED WITH AN ANTI-INFLAMMATORY MODULE AND METHODS FOR USING THE SAME - Disclosed are apparatuses for detecting glucose levels in a subject. The apparatuses include a glucose sensor coupled with an anti-inflammatory module. The apparatus is configured to monitor blood glucose by detecting the fluorescence generated by the sensor and simultaneously reduce the tissue inflammation reaction. Also disclosed are biosensor systems including the apparatuses and methods of using the biosensor systems. | 2011-10-27 |
20110262364 | Fluorescent Particles Comprising Nanoscale ZnO Layer and Exhibiting Cell-Specific Toxicity - A core-shell nanoparticle having a core that includes a fluorophore and a first oxide of a first metal and a shell that includes a second oxide of a second metal such that the first oxide and the second oxide are different. Also disclosed are methods relating to the core-shell nanoparticle. | 2011-10-27 |
20110262365 | METHODS OF DIAGNOSING HYPERSENSITIVITY TO A FEMALE REPRODUCTIVE HORMONE AND TREATING MEDICAL CONDITIONS ASSOCIATED WITH SAME - Provided are methods of diagnosing a medical condition associated with hypersensitivity to a female reproductive hormone in a subject, with the proviso that the medical condition is not estrogen dermatitis. The method is effected by administering into a skin of the subject at least one female reproductive hormone such as estriol or estrone, and monitoring a reaction to the female reproductive hormone on the skin, wherein a presence of the reaction above a predetermined threshold is indicative of the presence of the medical condition in the subject. Also provided are methods and computing platforms for treating the medical conditions associated with the hypersensitivity to the female reproductive hormone by desensitization. | 2011-10-27 |
20110262366 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE - The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy. | 2011-10-27 |
20110262367 | INSECTICIDAL GASSING AGENT CONTAINING ACTIVE INGREDIENT IN THE FORM OF A GRANULATE - The present invention relates to novel insecticidal fumigants which are prepared using active substance granules, to the processes for the preparation of such fumigants and to their use for controlling harmful and/or nuisance insects. | 2011-10-27 |
20110262368 | C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS - The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the general structure formula (VII): wherein L, R | 2011-10-27 |
20110262369 | CRYSTALLINE, ENANTIOMERICALLY PURE SALT FORM OF A BETA-AGONIST, AND THE USE THEREOF AS A DRUG - The invention relates to a crystalline, enantiomerically pure hydrochloride salt of N-(5-{2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methane sulfonamide, preferably N-(5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methane sulfonamide, and the effect thereof as a long-term betamimetic agent, alone or combined with at least one other active ingredient, in the treatment of respiratory diseases. | 2011-10-27 |
20110262370 | Shave Preparations - The shave preparation comprising water; one or more lipophilic skin conditioning agents; one or more thickening agents; one or more emulsifying agents; and one or more lubricants; a volatile self-foaming agent, wherein the composition is in the form of a self-foaming cream or lotion having an elastic modulus (G′) of about 150 Pa to about 1000 Pa having a low level of anionic surfactants and/or soap. | 2011-10-27 |
20110262371 | LIQUID CLEANING AND/OR CLEANSING COMPOSITION - The present invention relates to a liquid, cleaning and/or cleansing composition comprising abrasive cleaning particles. | 2011-10-27 |
20110262372 | Lactobacillus Fermentum SG-A95 for Improving Oral Bacterial Groups and Health Care Compositions Thereof - The present invention provides a strain of | 2011-10-27 |
20110262373 | PERSONALISED PHARMACEUTICAL COMPOSITION CONTAINING RETINOIC ACID, FOR ANTI-AGING OF THE SKIN - The invention relates to a personalised pharmaceutical composition for anti-aging of the skin, in the form of an ointment, comprising a first group of common active principles present in any formulation, formed by retinoic acid, at least one anti-inflammatory agent, at least one additional depigmenting agent, at least one anti-oxidant and at least one vitamin; and a second group of variable active principles present in variable quantities formulated according to the metabolic characteristics of the particular user. The anti-inflammatory agent is indomethacin. The depigmenting agents can be selected from the group consisting of hydroquinone, kojic acid, mequinol, phytic acid and alpha-arbutin. The anti-oxidants can be selected from the group consisting of lipoic acid, lycopene, coenzyme Q10, resveratrol, pycnogenol®, L-carnosine, taurine, N-acetylglucosamine, ascorbic acid, isoflavones and tocotrienol. The second group of variable active principles can comprise hyaluronic acid, aloe vera, bilberry glycolic extract, centella glycolic extract, allantoin, organic silicon, niacinamide and a cicatrizant. | 2011-10-27 |
20110262374 | NOVEL COMPOUND RAMALIN AND USE THEREOF - The present invention relates to a novel compound having excellent antioxidant activity, isolated from | 2011-10-27 |
20110262375 | Alkyl-Phenyl Silsesquioxane Resins Compositions - Compositions comprising a powder and an alkyl-phenyl silsesquioxane resin are disclosed. These compositions are particularly useful in a variety of personal or medical care compositions to enhance the durability and substantivity of powders after topical application. | 2011-10-27 |
20110262376 | COSMETIC COMPOSITION COMPRISING A POLYURETHANE BASED ON DIALKYL TARTRATE DIOL AND USES THEREOF - Cosmetic composition comprising, as film-forming agent, an aliphatic polyurethane based on dialkyl tartrate diol in a mixture of organic solvents and cosmetically acceptable ingredients. | 2011-10-27 |
20110262377 | Methods, Compositions and Articles for Olfactory-Active Substances - The present invention is directed to methods, compositions and articles comprising olfactory-active compositions. An article of the present invention comprises a structural component and an olfactory-active composition. The article may control the release, release rate or absorption of the olfactory-active composition. The article may be of various shapes and sizes. A method of use of an article comprises providing fragrance to an environment. | 2011-10-27 |
20110262378 | Rifaximin Complexes - There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex, and therapeutic uses of the complex. | 2011-10-27 |
20110262379 | Maleamic Acid Polymer Derivatives and Their Bioconjugates - The present invention is directed a method comprising administering a composition to an individual, wherein the composition comprises a plurality of conjugates, each conjugate in the plurality a protein derivatized with a water-soluble polymer, wherein the polymer is coupled to the protein via succinimide groups covalently attached to either cysteine sulfhydryl groups or lysine amino groups, and substantially all of the succinimide groups present in the composition are present in a ring-opened form. | 2011-10-27 |
20110262380 | THEAPEUTIC USE OF PROTEIN-POLYMER CONJUGATES - This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia. | 2011-10-27 |
20110262381 | FORMULATION FOR TREATMENT OF VAGINAL DRYNESS - The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition. | 2011-10-27 |
20110262382 | Dual-Action Pest Control Formulation and Method - The present disclosure provides a dual-action pest control formulation for controlling rodents and arthropods, the formulation including: a rodenticide; an insecticide; an optional attractant; and a carrier matrix. The present disclosure also provides a method of controlling rodents and arthropods, the method including: applying the dual action pest formulation to a target area. | 2011-10-27 |
20110262383 | Naphthalimide Dosing by N-Acetyl Transferase Genotyping - The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia. | 2011-10-27 |
20110262384 | Pharmaceutical Polypeptide Dry Powder Aerosol Formulation and Method of Preparation - Dispersible powder compositions suitable for inhalation are disclosed, the compositions including a human interleukin mutein (mhIL-4). | 2011-10-27 |
20110262385 | USE OF INTERLEUKIN-22 IN THE TREATMENT OF FATTY LIVER DISEASE - The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided. | 2011-10-27 |
20110262386 | METHODS OF TREATING INFLAMMATION - Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof. | 2011-10-27 |
20110262387 | METHODS AND MATERIALS FOR REDUCING OR SUPPRESSING AMYLOID DEPOSITION - This document relates to methods and materials for treating diseases and disorders that are caused by or associated with amyloid or amyloid-like proteins, such as Alzheimer's disease. For example, methods and materials for using interleukin-6 to reduce or suppress the deposition of Aβ are provided. | 2011-10-27 |
20110262388 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 2011-10-27 |
20110262389 | Tumor-derived Biological Antigen Presenting Particles - Disclosed is a biological anti-tumor approach that delivers specific antigen stimulation in the presence of co-stimulatory signals to the immune system. Tumor cells are engineered such that processed antigens and co-stimulatory molecules are incorporated into virus-like particles capable of modulating immune responses without cellular entry and nucleic acid genomic host cell integration. The invention describes constructing antigen presenting particles that will themselves present tumor antigens in an immunogenic fashion to therapeutically activate anti-tumor immunity within a mammalian host. | 2011-10-27 |
20110262390 | COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISORDERS - Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders. | 2011-10-27 |
20110262391 | CA9 GENE SINGLE NUCLEOTIDE POLYMORPHISMS PREDICT PROGNOSIS AND TREATMENT RESPONSE OF METASTATIC RENAL CELL CARCINOMA - Methods and compositions for providing a prognosis or diagnosis for a human patient having renal cell cancer are provided. The method relates to the discovery of SNPs which are associated with a favorable prognosis and response to therapy in RCC. | 2011-10-27 |
20110262392 | MEDIUM DERIVED FROM STEM CELLS AS A PHARMACEUTICAL COMPOSITION - The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis. | 2011-10-27 |
20110262393 | COMPOSITION COMPRISING MESENCHYMAL STEM CELLS OR CULTURE SOLUTION OF MESENCHYMAL STEM CELLS FOR THE PREVENTION OR TREATMENT OF NEURAL DISEASES - Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor. | 2011-10-27 |
20110262394 | DNA CONSTRUCTS ELICITING IMMUNE RESPONSE AGAINST FLAVIVIRUS AND EFFECTIVE ADJUVANTS - Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus. | 2011-10-27 |
20110262395 | SENSORY RECEPTORS FOR CHRONIC FATIGUE AND PAIN AND USES THEREOF - The present invention relates generally to the fields of pathological muscle pain/fatigue conditions. More specifically, the invention concerns methods and compositions useful for diagnosing and treating pathological muscle pain/fatigue conditions. | 2011-10-27 |
20110262396 | COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS - Provided are methods and compositions for using protease binding proteins in combination with other therapeutic agents to treat inflammatory disorders such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease (e.g., Crohn's and ulcerative colitis). The use of the protease binding protein allows a lower dose of the other therapeutic agents to be used in the methods and compositions, such that side effects of the other therapeutic agents are reduced or removed. | 2011-10-27 |
20110262397 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS - Various tetrahydropyrazolo[1,5-a]pyrimidine compounds, compositions, methods of making, and methods for the prevention and treatment of HCV infections and associated diseases are disclosed. The invention further relates to biomarkers for identification of HCV strains which are resistant to the tetrahydropyrazolo[1,5-a]pyrimidine compounds. | 2011-10-27 |
20110262398 | CARDIAC TREATMENT USING ANTI-FIBROTIC AGENTS - Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human. | 2011-10-27 |
20110262399 | PORPHOBILINOGEN DEAMINASE GENE THERAPY - The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3. | 2011-10-27 |
20110262400 | PROBIOTIC BACTERIAL MOLECULES AND THEIR USE IN METHODS TO TREAT/PREVENT INFECTION BY HARMFUL BACTERIA AND TO PROVIDE NUTRITIONAL HEALTH - This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal. | 2011-10-27 |
20110262401 | GRASS ENDOPHYTES - An endophyte or endophyte culture of | 2011-10-27 |
20110262402 | THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS - Provided is a pharmaceutical composition and a method for the treatment and/or prophylaxis of arthritis, inter alia, rheumatoid arthritis. The pharmaceutical composition comprises human mesenchymal stem cells, and the method comprises administering an effective amount human mesenchymal stem cells to a patient. | 2011-10-27 |
20110262403 | Method of accelerating osteogenic differentiation and composition thereof - The invention discloses a method of accelerating osteogenic differentiation and a composition thereof. The method comprises a step of adding type II collagen into stem/progenitor cells or osteoblasts to accelerate the osteogenic differentiation of the added cells, and the composition comprises type II collagen, and stem/progenitor cells or osteoblasts. Type II collagen can accelerate osteogenesis of mesenchymal stem cells (MSCs) much faster than does type I collagen. The said composition is effective to facilitate bone repair upon introduction of the composition into various osseous defects. | 2011-10-27 |
20110262404 | Novel Mesenchymal Stem Cells and Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 2011-10-27 |
20110262405 | APPARATUS, SYSTEM, AND METHOD FOR HARVESTING IMPROVED BONE GRAFT MATERIAL WITH REAMER-IRRIGATOR-ASPIRATOR (RIA) DEVICE - The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a Reamer-Irrigator-Aspirator (RIA) Device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include collagen based filters and may allow direct implant of small scale and larger scale matter in specific portions within the collagen itself. | 2011-10-27 |
20110262406 | COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that displace the polypyrimidine strand of target duplex and form a triple-stranded structure and hybrid duplex in a sequence specific manner with the polypurine strand of the target duplex. The triplex-forming molecules include a mixed-sequence “tail” which increases the stringency of binding to the target duplex, improves the frequency of modification at the target site, and reduces the requirement for a polypurine:polypyrimidine stretch. Methods for using the triplex-forming molecules in combination with one or more donor oligonucleotides for targeted modification of sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV) are also disclosed. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided. | 2011-10-27 |
20110262407 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. | 2011-10-27 |
20110262408 | FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 2011-10-27 |
20110262409 | COMPOSITION COMPRISING A COMBINATION OF AN ELDER EXTRACT AND A STRAIN OF L. PARACASEI, L. CASEI, L. BULGARICUS OR S. THERMOPHILUS - The invention relates to a composition comprising a combination of an elder extract ( | 2011-10-27 |
20110262410 | USE OF LIVE BACTERIA FOR GROWTH PROMOTION IN ANIMALS - The present invention relates to the use of F4 | 2011-10-27 |
20110262411 | BACTERIOPHAGE DERIVED METHODS TO CONTROL LACTIC ACID BACTERIAL GROWTH - Compositions and methods for protection against bacterial contamination are disclosed Antibacterial proteins and methods of use thereof are also disclosed | 2011-10-27 |
20110262412 | BACTERIOCIN BASED METHODS TO CONTROL LACTIC ACID BACTERIAL GROWTH - The present invention relates to compositions and methods for protection against bacterial contamination. The invention provides bactericidal yeast expressing bacteriocin proteins and methods of using the bactericidal yeast. | 2011-10-27 |
20110262413 | METHODS OF REDUCING EXTRAVASATION OF INFLAMMATORY CELLS - A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease. | 2011-10-27 |
20110262414 | HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 2011-10-27 |
20110262415 | ERYTHROCYTE-BASED DELIVERY SYSTEM, METHOD OF PREPARATION AND USES THEREOF - The invention relates to a cell-based drug delivery system comprising magneto nanoparticles, erythrocytes and a fusion-protein, its preparation and uses thereof in particular as a delivery system for biologically active compounds. | 2011-10-27 |
20110262416 | Bacillus subtilis strain having antagonistic activity for controlling plant diseases - A novel strain of | 2011-10-27 |
20110262417 | COMPOSITION USEFUL FOR THE PREVENTION OR REDUCTION OF THE PROGRESSION OF PROSTATE CANCER - It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer. | 2011-10-27 |
20110262418 | COMPOSITION AND METHODS FOR RELIEF OF NEUROPATHOLOGICAL PAIN - The formulations of the present disclosure alter the perception of pain, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as fibromyalgia. The present disclosure encompasses formulations for the relief of symptoms associated with neuropathy pain, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, and folic acid. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and cholinebitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating neuropathy related pain in subject animal or human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, and water. | 2011-10-27 |
20110262419 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF - This invention provides chimeric molecules that are catalytic antagonists of a target molecule. The catalytic antagonists of this invention preferably comprise a targeting moiety attached to an enzyme that degrades the molecule specifically bound by the targeting moiety. The catalytic antagonists of this invention thus bind to a target recognized by the targeting moiety (e.g., a receptor) the enzyme component of the chimera then degrades all or part of the target. This typically results in a reduction or loss of activity of the target and release of the chimeric molecule. The chimeric molecule is then free to attack and degrade another target molecule. | 2011-10-27 |
20110262420 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE - An inhalant containing a lecithinized superoxide dismutase (hereinafter referred to as PC-SOD) which effectively exerts the effect of superoxide dismutase (SOD) as an active ingredient, particularly for treatment of idiopathic (acute) or chronic interstitial pneumonia, is provided. The inhalant includes a PC-SOD represented by the following general formula (I): | 2011-10-27 |
20110262421 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, OR FEED FOR INTESTINAL DISEASE - It is intended to provide a pharmaceutical composition, a food or drink, or a feed which has an effect on the prevention and/or treatment of an intestinal disease such as ulcerative colitis, Crohn's disease or irritable bowel syndrome. A preferred embodiment is the pharmaceutical composition, food or drink, or feed which contains lactoperoxidase as an active ingredient and has an effect on the prevention and/or treatment of an intestinal disease, wherein the intestinal disease is at least one disease selected from ulcerative colitis, Crohn's disease and irritable bowel syndrome. | 2011-10-27 |
20110262422 | ORALLY ADMINISTRABLE DOSAGE FORMS COMPRISING ANGIOGENIN AND USES THEREOF - The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or for the protein to be encapsulated or subjected to any other mechanism to improve its oral bioavailability. | 2011-10-27 |
20110262423 | SUPPRESSION OF CANCER - The present invention relates to polypeptides for use in suppressing cancer and cancer disorders. The treatment employs use of a non-cytotoxic protease, which is targeted to the cancer cell, and, when so delivered, the protease is internalised and inhibits secretion from the cancer cell. | 2011-10-27 |
20110262424 | RECOMBINANTLY PRODUCED HUMAN FACTOR VIII AND IX - A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Galα-3Gal. | 2011-10-27 |
20110262425 | THERAPEUTIC AGENT FOR MLL LEUKEMIA AND MOZ LEUKEMIA OF WHICH MOLECULAR TARGET IS M-CSF RECEPTOR, AND USE THEREOF - An objective of the present invention is to provide therapeutic agents for MLL leukemia and MOZ leukemia, which include an M-CSF receptor inhibitor as an active ingredient. Another objective of the present invention is to provide methods of screening for pharmaceutical compositions that treat or prevent leukemia by suppressing the expression or activity of M-CSF receptor. Still another objective of the present invention is to provide methods of testing for leukemia, which include the step of determining the expression level of an M-CSF receptor. The present inventors conducted dedicated studies, and as a result revealed that the M-CSF receptor (M-CSFR, CSF1R, c-FMS, or CD115) is highly expressed in cells having the activity of inducing MLL or MOZ leukemia (leukemia stem cells), both of which are intractable acute leukemia. Specifically, the present inventors discovered that the M-CSF receptor signal is closely associated with the leukemia onset. | 2011-10-27 |
20110262426 | METHODS AND KITS USED IN IDENTIFYING GLIOBLASTOMA - The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome. | 2011-10-27 |
20110262427 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM - The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2011-10-27 |
20110262428 | TREATING CANCER BY MODULATING RNA HELICASES - The present invention relates to a method for treating cancer in a subject by inhibiting DHX36, by administering to said subject a therapeutically effective amount of a modulator of DHX36. | 2011-10-27 |
20110262429 | HUMAN TIMP-1 ANTIBODIES - Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis. | 2011-10-27 |
20110262430 | NOVEL ANTIBODIES - The present invention relates to antibodies or antigen binding fragments thereof which specifically binds to IGF-IR, specifically hIGF-1R. Also disclosed are antibody preparations comprising antibodies or antigen binding fragments of the invention. Methods of producing such antibodies or antigen binding fragments and uses thereof are also included within the scope of the present invention. | 2011-10-27 |
20110262431 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY COMPOSITION WHICH SPECIFICALLY BINDS TO CCR4 - A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament. | 2011-10-27 |
20110262432 | MUTATED NETRIN 4 PROTEINS, FRAGMENTS THEREOF AND THEIR USES AS DRUGS - A mutated protein includes the sequence of wild type netrin 4, represented by SEQ ID NO: 2, wherein at least one amino acid of the amino acids at position (13, 68, 183, 205, 234, 331, 332, 353, 472, 515, 589, 625, 626, 627) and (628) is mutated enabling thus to confer 1 to 15 mutations to the wild type protein, or, truncated protein derived from the mutated protein, wherein the 19 first contiguous, or the 31 first contiguous amino acids at the N-terminus part of the mutated protein are deleted; and/or the mutated protein being deleted of all amino acids located after the amino acid in position (477) or of all amino acids located after the amino acid in position (515). | 2011-10-27 |
20110262433 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2011-10-27 |
20110262434 | Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies - The present disclosure provides improved methods for identifying breast cancer patients that receive an increased benefit from the addition of a HER | 2011-10-27 |
20110262435 | IL-13 BINDING AGENTS - Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed. | 2011-10-27 |
20110262436 | TREATMENT METHOD - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 2011-10-27 |
20110262437 | USE OF ERBB4 AS A PROGNOSTIC AND THERAPEUTIC MARKER FOR MELANOMA - It is disclosed herein that members of the protein tyrosine kinase (PTK) family are highly mutated in patients with melanoma. Described herein are novel somatic mutations in the ERBB4 gene that result in increased kinase activity, transformation ability and anchorage-independent growth. These ERBB4 mutations contribute to the tumorogenicity of melanoma. Thus, provided herein is a method of predicting the prognosis of a patient with melanoma by detecting the presence or absence of a mutation in the ERBB4 gene. In some examples, the ERBB4 mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbering based on SEQ ID NO: 1). Also provided are methods of selecting a patient as a candidate for treatment with an ERBB4 and/or PI3K/AKT pathway inhibitor, and a method of identifying a therapeutic agent for the treatment of a subject diagnosed with melanoma. Oligonucleotides that specifically hybridize with an ERBB4 nucleic acid molecule comprising a novel mutation, and arrays comprising such oligonucleotides, are also provided. | 2011-10-27 |
20110262438 | BIOLOGICAL MATERIALS RELATED TO CXCR7 - The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. | 2011-10-27 |
20110262439 | BISPECIFIC SINGLE CHAIN ANTIBODIES WITH SPECIFICITY FOR HIGH MOLECULAR WEIGHT TARGET ANTIGENS - The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Furthermore, the invention provides pharmaceutical compositions comprising bispecific single chain antibodies of the invention, medical uses of the same and methods for the treatment of diseases comprising the administration of bispecific single chain antibodies of the invention. | 2011-10-27 |
20110262440 | TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA - The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof. | 2011-10-27 |
20110262441 | METHOD FOR SELECTIVE CONTROL OF HELPER T CELL FUNCTION - The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and/or an anti-allergic action. | 2011-10-27 |
20110262442 | COMPOSITIONS FOR TREATING CNS DISORDERS - The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof. | 2011-10-27 |
20110262443 | Epitopes Of Il-17a And Il-17f And Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 2011-10-27 |
20110262444 | FORM-SPECIFIC ANTIBODIES FOR NAG-1 (MIC-1, GDF-15), H6D AND OTHER TGF-BETA SUBFAMILY AND HEART DISEASE AND CANCER DIAGNOSES - A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer. | 2011-10-27 |
20110262445 | ANTI-IL-12/IL-23 ANTIBODIES - The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R β2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1. | 2011-10-27 |
20110262446 | USE OF IGF-II/IGF-IIE BINDING PROTEINS FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS - Methods of using proteins that bind to IGF-II and/or IGF-IIE for the treatment or prevention of systemic sclerosis-associated pulmonary fibrosis are described. | 2011-10-27 |
20110262447 | HUMAN SYNTHETIC SINGLE-CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND THEIR USES - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention. | 2011-10-27 |
20110262448 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 2011-10-27 |
20110262449 | METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT - The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome. | 2011-10-27 |
20110262450 | MODULATORS OF MONOGLYCERIDE LIPASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of monoglyceride lipase (MGLL), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-10-27 |
20110262451 | MODULATORS OF ISOVALERYL-COENZYME A DEHYDROGENASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-10-27 |
20110262452 | ANTI-HEPSIN ANTIBODIES AND METHODS USING SAME - The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies. | 2011-10-27 |
20110262453 | Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment - The present invention relates to a method of predicting response of a cancer cell tissue to IGF-IR treatment. The inventors have observed a direct relationship between the expression of survivin, ErbB | 2011-10-27 |
20110262454 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38 | 2011-10-27 |
20110262455 | TREATMENT OF PROLIFERATIVE DISORDERS WITH A DEATH RECEPTOR AGONIST - A method of treating a proliferative disorder, and a pharmaceutical composition for use in such a method, comprises administering to the patient a combination of an agonist of a death receptor and an antagonist of Egr-1. The death receptor agonist and the Egr-1 antagonist may be administered sequentially, separately or in combination | 2011-10-27 |